Fewer bone histomorphometric abnormalities with intermittent than with continuous slow-release sodium fluoride therapy.
To help resolve the uncertainty whether sodium fluoride (NaF) therapy should be given intermittently or continuously, we examined iliac crest bone biopsies (before and after treatment) and fragility fracture rates in 35 intermittently treated (group I) and 69 continuously treated (group C) patients; all received calcium. The following statistically significant results were obtained. Reduction in vertebral fracture rate was similar in the two groups. Trabecular thickness and the structurally more important mineralized thickness increased only in group I. Group I also accumulated less excess osteoid (surface, volume). Mean osteoid thickness did not change in either group because of a bimodal distribution of wide seams with osteoblasts and double tetracycline labels, and thin seams without osteoblasts or labels. Osteoid was lamellar. Osteoid in abnormal sites (within bone marrow or bone, or around osteocytes) was found less frequently in group I. Adjusted apposition rate declined and mineralization lag time increased in both groups because of extended unlabelled osteoid seams. Erosion surface increased only in group C. Hook and/or tunnel erosion was seen less frequently in group I; it was closely associated with osteoid in abnormal sites and correlated with osteoid surface. Extended osteoid surface may have forced osteoclasts to hollow out trabeculae, leaving the empty osteoid shell in marrow. Excess osteoid volume and eroded surface and osteoid and erosion in abnormal sites correlated with bone fragility in group C. We conclude that intermittent therapy is to be preferred because it (1) increased mineralized trabecular thickness, (2) did not cause excessive osteoid accumulation and erosion, (3) showed less osteoid and erosion in abnormal sites and (4) led to a similar reduction in the vertebral fracture rate as did continuous treatment. The question of whether intermittency of therapy has some other effect independent of the cumulative dose of fluoride administered cannot be answered by this study.
Schnitzler
C M
CM
Department of Orthopaedic Surgery, Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa.
Wing
J R
JR
Raal
F J
FJ
van der Merwe
M T
MT
Mesquita
J M
JM
Gear
K A
KA
Robson
H J
HJ
Shires
R
R
D000328:Adult; D000368:Aged; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology; D003692:Delayed-Action Preparations; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology; D012969:Sodium Fluoride / Q000008:administration & dosage*; D016103:Spinal Fractures / Q000517:prevention & control
D003692:Delayed-Action Preparations; D012969:Sodium Fluoride